Transplantation of Microbes of Fecal Origin for Prevention and Treatment of Metabolic Syndrome and Non Alcoholic Fatty Liver Disease
Transplantation of Microbes of Fecal Origin for Prevention and Treatment of Metabolic Syndrome and Non Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) occurs when excess fat is deposited in the liver. Almost all patients also have obesity and insulin resistance (the inability of the body to effectively use insulin). Obesity and NAFLD are intricately intertwined and are increasing in incidence. While weight loss is the most effective therapy for NAFLD, the investigators' efforts are failing and in the next generation it will become the most common cause of liver failure in Canada. Recently, researchers have focused on the potential use of altering the composition of bacteria in the gut (microbiome) to alter absorption of energy from food, deposition of fat and resistance to insulin. This study will determine if transplantation of bacteria from the stool of a healthy volunteer into an individual with metabolic syndrome and NAFLD (i.e. fecal microbiota transplant/FMT) can alter insulin resistance and reduce the amount of fat deposited in the liver. FMT is being studied to treat several clinical conditions and is now standard of care for the treatment of refractory Clostridium difficile infection. Investigators are proposing a randomized controlled pilot study of FMT in 21 patients to determine the feasibility and to inform us of changes needed for a larger study.
Obesity and obesity-related disorders such as metabolic syndrome, Type 2 Diabetes (DM2), and NAFLD are of increasing concern worldwide. Metabolic syndrome refers to the clustering of 3 out of 5 parameters - abdominal obesity, elevated blood pressure, elevated fasting glucose, elevated triglyceride level, and low high-density lipoprotein cholesterol (HDL-C) level. The prevalence of metabolic syndrome is approximately 20-25% in North America. Those with metabolic syndrome are at increased risk for DM2 and cardiovascular disease.
Metabolic syndrome, DM2 and NAFLD are all marked by insulin resistance and are intricately linked with obesity. NAFLD is currently the most common liver disease in developed countries such as Canada. About 10-20% of patients with NAFLD progress to non-alcoholic steatohepatitis (NASH) which is characterized by inflammation and fat deposition. Unfortunately, NASH is a major cause of cirrhosis in North America.
Gut Microbiota, Obesity, DM2, and NAFLD Very strong support for the hypothesis of the gut microbiome inducing insulin resistance was found in a recent randomized control trial which showed that fecal transplantation from lean healthy donors into human patients with metabolic syndrome resulted in improved insulin sensitivity. This improvement correlated to an increase in the prevalence of butyrate-producing bacteria. Since butyrate helps prevent programmed cell death in the mucosal cells of the colon, preserving the integrity of the intestinal mucosa may prevent migration of endotoxin from the gut to the liver and induction of insulin resistance. Larger metagenome wide association studies of the fecal microbiome confirmed this finding that butyrate-producing bacteria including Clostridiales spp,C. rectales, Faecalibacterium prausnitzii, Roseburia intestinalis and R.inulinvorans appear to be less prevalent in DM2 than in healthy controls.
Differences in the microbiome between obese patients and those with DM2 versus those with a normal body mass index have been reported in many publications. There is evidence that the altered flora can increase the efficiency of release of calories from food. In a study of obese human twins, the decrease in Bacteroidetes proportion with increase in Firmicutes proportion correlated with the enrichment of microbial genes encoding key enzymes involved in carbohydrate metabolism, potentially leading to increased digestion of food and supply of energy in the form of short chain fatty acids (SCFA) to the host. Transfer of the gut microbiota from obese mice or from obese humans into germ-free mice reproduced the obese phenotype. Differences in microbiota composition have even been documented between children with obesity and those children who are lean, suggesting that microbiota changes may occur early in life. Decrease in the ratio of the number of firmicutes/bacteroidetes were associated with weight loss in humans. Other human gut organisms such as Akkermansia muciniphilia and Enterobacter cloacae B29 have been implicated with obesity and DM2. A high concentration of gut Beta proteobacteria was associated with the development of diabetes possibly via an inflammatory response incited by the endotoxin within these Gram negative rods. In fact antibiotic administration in some animal models has led to reduced numbers of both aerobic and anaerobic bacteria which increases insulin sensitivity as well as in plasma adiponectin levels, which correlate with insulin sensitivity. Changes in the gut microbiota associated with obesity have been found to activate Toll like receptors and thus GI inflammation with resulting insulin resistance. Very recently it was found that artificial sweeteners despite being "no-calorie" can exacerbate glucose intolerance, the effect mediated via a change in the microbiome.
Compared to both healthy controls and simple steatosis patients, patients with NASH have a lower percentage of the phylum Bacteroidetes, a finding similar to that of the gut microbial flora in obese human subjects. Microbial fermentation products like ethanol in the gut are key factors to induce obesity in mice and may be related to the pathogenesis of fatty liver disease. Elevated systemic ethanol levels even in the absence of any ethanol ingestion have been noted in patients with NASH compared to controls, suggesting that ethanol-producing microbes might be related to the pathogenesis of NASH in humans.Certain microbiomes can also lead to higher monosaccharide absorption from the gut lumen, which can promote de novo fatty acid and triglyceride production in the liver. It has been found that the hepatic kupffer cell activation in mice seems to contribute to the pathogenesis of NAFLD and that this can be induced by microbial endotoxin-related chronic inflammation. Chronic endotoxemia is associated with the severity of NAFLD. Increased intestinal permeability has similarly been documented in DM2 and metabolic syndrome and likely plays a key role in the pathophysiology of these disorders. Overall these findings suggest that preventive or therapeutic interventions such as fecal transplantation may lead to improvement in the status of obesity, metabolic syndromes, and NASH or NAFLD,and possibly even atherosclerosis.
Fecal Microbial Transplantation has been used extensively in humans with recurrent C.difficile infection and has been found to be safe, effective and well tolerated. Frozen stool has been found to be equally safe and effective to fresh stool for transplant. This procedure has become well accepted and is now considered the standard of practice for patients with recurrent C.difficile, and is included in newer practice guidelines. Its use in metabolic syndromes is new, but the safety data from the much larger experience in patients with C.difficile is very reassuring.
Goal:
• To determine the impact of alterations of the gut microbiome on parameters of insulin resistance and on liver fat content.
Rationale:
As mentioned in the background review there is extensive animal and also moderately extensive human studies demonstrating that alteration in the microbiome is associated with metabolic syndrome and NAFLD. There is also extensive biochemical rationale for why microbiome changes could lead to the changes in the metabolic outcomes in humans.
Justification of Innovation:
The inability of existing therapies to control weight gain, obesity and associated liver diseases in individuals with metabolic disorders is a major public health concern. The potential of gut microbial alteration to prevent and control metabolic disorders (duplicating the success of FMT for Clostridium difficile infection) would be an important advance. This will be a proof of concept study which will enable further more targeted innovations of the gut microbiome to control the metabolic syndrome and NAFLD.